Advancement in early diagnosis of polycystic ovary syndrome: biomarker-driven innovative diagnostic sensor

IF 5.3 2区化学 Q1 CHEMISTRY, ANALYTICAL

Microchimica Acta Pub Date : 2025-05-01 DOI:10.1007/s00604-025-07187-w

Aniket Nandi, Kamal Singh, Kalicharan Sharma

{"title":"Advancement in early diagnosis of polycystic ovary syndrome: biomarker-driven innovative diagnostic sensor","authors":"Aniket Nandi, Kamal Singh, Kalicharan Sharma","doi":"10.1007/s00604-025-07187-w","DOIUrl":null,"url":null,"abstract":"<div><p>Polycystic ovary syndrome (PCOS) is a heterogeneous multifactorial endocrine disorder that affects one in five women around the globe. The pathology suggests a strong polygenic and epigenetic correlation, along with hormonal and metabolic dysfunction, but the exact etiology is still a mystery. The current diagnosis is mostly based on Rotterdam criteria, which resulted in a delayed diagnosis in most of the cases, leading to unbearable lifestyle complications and infertility. PCOS is not new; thus, constant efforts are made in the field of biomarker discovery and advanced diagnostic techniques. A plethora of research has enabled the identification of promising PCOS diagnostic biomarkers across hormonal, metabolic, genetic, and epigenetic domains. Not only biomarker identification, but the utilization of biosensing platforms also renders effective point-of-care diagnostic devices. Artificial intelligence also shows its power in modifying existing image-based analysis, even developing symptom-based prediction systems for the early diagnosis of this multifaceted disorder. This approach could affect the future management and treatment direction of PCOS, decreasing its severity and improving the reproductive life of women. The rationale of the current review is to identify the advancements in understanding the pathophysiology through biomarker discovery and the implementation of modern analytical techniques for the early diagnosis of PCOS.</p><h3>Graphical Abstract</h3>\n<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":705,"journal":{"name":"Microchimica Acta","volume":"192 5","pages":""},"PeriodicalIF":5.3000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Microchimica Acta","FirstCategoryId":"92","ListUrlMain":"https://link.springer.com/article/10.1007/s00604-025-07187-w","RegionNum":2,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, ANALYTICAL","Score":null,"Total":0}

引用次数: 0

Abstract

Polycystic ovary syndrome (PCOS) is a heterogeneous multifactorial endocrine disorder that affects one in five women around the globe. The pathology suggests a strong polygenic and epigenetic correlation, along with hormonal and metabolic dysfunction, but the exact etiology is still a mystery. The current diagnosis is mostly based on Rotterdam criteria, which resulted in a delayed diagnosis in most of the cases, leading to unbearable lifestyle complications and infertility. PCOS is not new; thus, constant efforts are made in the field of biomarker discovery and advanced diagnostic techniques. A plethora of research has enabled the identification of promising PCOS diagnostic biomarkers across hormonal, metabolic, genetic, and epigenetic domains. Not only biomarker identification, but the utilization of biosensing platforms also renders effective point-of-care diagnostic devices. Artificial intelligence also shows its power in modifying existing image-based analysis, even developing symptom-based prediction systems for the early diagnosis of this multifaceted disorder. This approach could affect the future management and treatment direction of PCOS, decreasing its severity and improving the reproductive life of women. The rationale of the current review is to identify the advancements in understanding the pathophysiology through biomarker discovery and the implementation of modern analytical techniques for the early diagnosis of PCOS.

Graphical Abstract

查看原文本刊更多论文

多囊卵巢综合征早期诊断的进展：生物标志物驱动的创新诊断传感器

多囊卵巢综合征（PCOS）是一种异质性多因素内分泌紊乱，影响全球五分之一的女性。病理提示与多基因和表观遗传相关，以及激素和代谢功能障碍，但确切的病因仍是一个谜。目前的诊断主要基于鹿特丹标准，这导致大多数病例的诊断延迟，导致无法忍受的生活方式并发症和不孕症。多囊卵巢综合征并不新鲜；因此，在生物标志物的发现和先进的诊断技术领域不断努力。大量的研究已经能够在激素、代谢、遗传和表观遗传领域鉴定出有前途的多囊卵巢综合征诊断生物标志物。不仅生物标志物鉴定，而且利用生物传感平台也提供了有效的即时诊断设备。人工智能在修改现有的基于图像的分析，甚至开发基于症状的预测系统以早期诊断这种多方面疾病方面也显示出其力量。该方法可以影响PCOS的未来管理和治疗方向，降低其严重程度，改善女性的生殖生活。本综述的基本原理是通过生物标志物的发现和现代分析技术的实施来确定PCOS早期诊断的病理生理学进展。图形抽象

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Microchimica Acta 化学-分析化学

CiteScore

9.80

自引率

5.30%

发文量

410

审稿时长

2.7 months

期刊介绍： As a peer-reviewed journal for analytical sciences and technologies on the micro- and nanoscale, Microchimica Acta has established itself as a premier forum for truly novel approaches in chemical and biochemical analysis. Coverage includes methods and devices that provide expedient solutions to the most contemporary demands in this area. Examples are point-of-care technologies, wearable (bio)sensors, in-vivo-monitoring, micro/nanomotors and materials based on synthetic biology as well as biomedical imaging and targeting.